Patrick D. Yeramian - 15 May 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Reporting relationship: Chief Medical Officer
Issuer ticker: AMLX
Reported as of: 15 May 2023
Net transaction value: -$279,368
SEC form: 4
Accepted by SEC: 17 May 2023, 16:58:42 UTC
Prior SEC filing: 19 Apr 2023
Next SEC filing: 11 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Joshua B. Cohen, as Attorney in Fact

Key filing fact

Patrick D. Yeramian filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 17 May 2023.

Key facts

This page summarizes Patrick D. Yeramian's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 May 2023, 16:58.

Change

Previous filing in this sequence was filed on 19 Apr 2023.
Current net transaction value: -$279,368.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMLX transaction

Common Stock

Options Exercise

Transaction value: $814
Shares: +2,201
Change %: +1.1%
Price: $0.3700^*
Shares after: 210,618
Date: 15 May 2023
Ownership: Direct
Footnotes: F1

AMLX transaction

Common Stock

Options Exercise

Transaction value: $67,176
Shares: +9,764
Change %: +4.6%
Price: $6.88
Shares after: 220,382
Date: 15 May 2023
Ownership: Direct
Footnotes: F1

AMLX transaction

Common Stock

Sale

Transaction value: $347,358
Shares: -11,965
Change %: -5.4%
Price: $29.03
Shares after: 208,417
Date: 15 May 2023
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMLX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -2,201
Change %: -13%
Price: $0.000000
Shares after: 15,404
Date: 15 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,201
Exercise price: $0.3700
Footnotes: F1, F3

AMLX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -9,764
Change %: -22%
Price: $0.000000
Shares after: 33,770
Date: 15 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,764
Exercise price: $6.88
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.00 to $29.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F3

As of the date of this filing, 2,201 shares subject to the option are vested and exercisable. 15,404 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.

Footnote F4

As of the date of this filing, 13,746 shares subject to the option are vested and exercisable. 23,600 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023.